|
Website:
http://www.akorn.com
Phone: +1 847 279-6100 |
Address:
2500 Millbrook Drive
Buffalo Grove, ILLINOIS 60089 |
Company Description
Akorn, Inc.. The Group's principal activities are to manufacture and market diagnostic and therapeutic pharmaceuticals in specialty areas such as ophthalmology, rheumatology, anesthesia and antidotes. The activities are carried out through three business segments: Ophthalmic, Injectable and Contract services. The Ophthalmic segment markets diagnostic and therapeutic ophthalmic pharmaceutical products. The Injectable segment markets specialty injectable pharmaceutical products, including antidotes, anesthesia, and products used in the treatment of rheumatoid arthritis and pain management. The Contract services segment manufacture products for third party pharmaceutical and biotechnology customers based on their specifications. The Group's customers include physicians, optometrists, hospitals, wholesalers, group purchasing organizations and other pharmaceutical companies. It operates only in the United States. Injectable Products accounted for , 60% of 2006 revenues, Ophthalmic Instruments, 27% and Contract Services, 13%
Key People
| President & Chief Executive | Arthur S. Przybyl |
| Senior Vice President, Chief Financial Officer, Secretary & Treasurer | Jeffrey A. Whitnell |
| Chairman | Dr. John N. Kapoor |
Related Business Topics
1-9 |
A |
B |
C |
D |
E |
F |
G |
H |
I |
J |
K |
L |
M |
N |
O |
P |
Q |
R |
S |
T |
U |
V |
W |
X |
Y |
Z
A
Akorn, Inc. / Ophthalmic Division
Producer of non-injectable ophthalmic diagnostic agents and pharmaceutical products. Products are sold to multiple industries. This company was capitalized by corporate investment.
www.akorn.com
Producer of non-injectable ophthalmic diagnostic agents and pharmaceutical products. Products are sold to multiple industries. This company was capitalized by corporate investment.
www.akorn.com
Breaking News
Forbes.com - November 23, 2008 8:25 AM
S&P 500 Earnings - Weekly S&P 500 Earnings - Day Ahead Non S&P 500 - Weekly Non S&P 500 - Day Ahead ConferenceCall/Webcast - Weekly ConferenceCall/Webcast - Day Meetings - Weekly S&P 500 Earnings - Monthly Economic Indicators IPO events Dividends Daily ...
Forbes.com - November 22, 2008 7:13 PM
Akorn, Inc. (NASDAQ: AKRX) a specialty pharmaceutical company, today reported financial results for the third quarter ended September 30, 2008. Total revenue for the third quarter 2008 was $31.9 million, versus $15.8 million in the third quarter 2007, ...
Forbes.com - November 22, 2008 6:56 PM
ews Nov 3 (Reuters) - Akorn Inc: * Reports record third quarter 2008 revenues of $31.9 million; earnings per share of $0.03 * Q3 revenue $31.9 million versus $15.8 million * Reuters Estimates Q3 earnings per share view $0.01, revenue view $30.30 million ...
Forbes.com - November 22, 2008 3:08 AM
Akorn-Strides, LLC today announced that the U.S. Food and Drug Administration has granted approval for an Abbreviated New Drug Application (ANDA) for Pamidronate Disodium Injection, 3 mg/mL and 9 mg/mL in 10 mL vials. Akorn-Strides, LLC is a Joint ...
Forbes.com - November 21, 2008 11:19 PM
REUTERS, Non-S&P Corporate earnings for US comanies for Monday Nov 03, 2008. S&P 500 Earnings - Weekly S&P 500 Earnings - Day Ahead Non S&P 500 - Weekly S&P 500 Earnings - Monthly ConferenceCall/Webcast - Weekly ConferenceCall/Webcast - Day Meetings - ...
More Akorn, Inc. News
